维康药业(300878) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥178,726,158.13, representing a 5.39% increase compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2022 was ¥36,945,214.13, an increase of 27.63% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥36,037,284.55, up 26.89% from the previous year[5]. - Total operating revenue for Q3 2022 was CNY 474,349,508.65, a decrease of 5.4% compared to CNY 501,412,396.64 in Q3 2021[21]. - Net profit for Q3 2022 reached CNY 94,643,387.92, representing an increase of 2.0% from CNY 92,766,143.34 in Q3 2021[23]. - Earnings per share for Q3 2022 were CNY 0.6487, compared to CNY 1.1527 in Q3 2021, indicating a decline of 43.7%[23]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,804,727,873.40, reflecting a 6.58% increase from the end of the previous year[5]. - Total assets as of Q3 2022 amounted to CNY 1,804,727,873.40, an increase of 6.6% from CNY 1,693,307,837.66 at the end of Q3 2021[21]. - Total liabilities increased to CNY 353,241,072.97 in Q3 2022, up 24.3% from CNY 284,283,154.00 in Q3 2021[21]. - The company's total liabilities to equity ratio stood at 0.243, indicating a relatively low level of financial leverage[21]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥57,006,680.59, showing a significant increase of 170.88%[13]. - The net cash flow from operating activities for the period was ¥57,006,680.59, a significant improvement compared to the previous period's net cash flow of -¥80,427,600.07[24]. - Total cash inflow from operating activities was ¥461,139,874.99, while cash outflow was ¥404,133,194.40, resulting in a net cash inflow[24]. - Cash flow from investment activities was negative at -¥276,850,692.98, worsening from -¥158,106,700.89 in the previous period[24]. - The net cash flow from financing activities was ¥132,412,177.85, a recovery from the previous period's net outflow of -¥37,541,272.46[25]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 11,090[15]. - Liu Zhongliang holds 60.89% of shares, amounting to 88,162,900 shares[15]. - Total restricted shares at the end of the period is 104,964,348, with 46,650,821 shares newly restricted during the period[17]. - The company plans to lift restrictions on shares for major shareholders on August 24, 2023[17]. - Liu Zhongliang and Liu Zhongjiao are identified as siblings, indicating potential influence on shareholding dynamics[16]. Research and Development - Research and development expenses increased by 80.05% to ¥28,067,342.97, primarily due to increased costs associated with new drug development[12]. - Research and development expenses for Q3 2022 were CNY 28,067,342.97, up 80.0% from CNY 15,588,382.73 in Q3 2021, reflecting a strong focus on innovation[21]. Inventory and Fixed Assets - The company reported a significant increase in inventory, which rose by 55.38% to ¥201,200,040.41, mainly due to stockpiling by subsidiaries[10]. - Inventory increased significantly from 129,492,497.74 to 201,200,040.41, representing a growth of approximately 55.4%[19]. - Fixed assets rose from 301,928,929.86 to 545,931,172.52, an increase of around 80.8%[19]. Other Financial Metrics - The company's basic earnings per share decreased by 29.09% to ¥0.2552[5]. - The weighted average return on net assets was 2.58%, an increase of 0.49% compared to the previous year[5]. - Cash and cash equivalents decreased from 280,795,523.15 to 192,700,608.64, a decline of approximately 31.3%[19]. - Accounts receivable increased from 373,660,578.13 to 410,939,715.85, an increase of about 10%[19]. - The company received ¥80,000,000.00 in borrowings during the period, an increase from ¥50,000,000.00 in the previous period[25]. - The company paid ¥43,066,988.82 in dividends and interest, a decrease from ¥75,841,272.46 in the previous period[25]. Audit Information - The company did not conduct an audit for the third quarter report[26].